Actelion Share Price Xetra

Stocks

31/17/31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
09/17/09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/17/09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/17/09	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/17/22	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/17/18	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/17/20	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/17/18	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/17/05	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/17/31	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
23/17/23	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/20/06	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/17/31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/17/30	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/17/16	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
16/17/16	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/18/29	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/18/29	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/18/22	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/17/31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/17/30	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACTELION	-.--%	-.--%	-	-	0
WUXI APPTEC CO., LTD.	-1.79%	-2.27%	+43.23%	+88.96%	6.8TCr
ARGENX SE	-2.06%	-0.18%	+39.67%	+86.44%	6.49TCr
INSMED INCORPORATED	-0.31%	+6.54%	-12.96%	+378.92%	2.76TCr
BIONTECH SE	+0.86%	+1.65%	-7.74%	-14.95%	2.61TCr
WUXI BIOLOGICS (CAYMAN) INC.	-3.00%	-2.90%	+33.13%	+12.54%	2.57TCr
GENMAB A/S	-1.46%	+0.42%	+23.61%	-18.61%	2.01TCr
PHARMAESSENTIA CORPORATION	-2.96%	-15.21%	+216.20%	+368.10%	1.72TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-4.88%	-6.60%	+531.89%	1.49TCr
EXELIXIS, INC.	-0.20%	+8.37%	+55.78%	+164.98%	1.46TCr
Average	-1.24%	+0.26%	+42.70%	+177.58%	3.1TCr
Weighted average by Cap.	-1.52%	+0.18%	+38.37%	+137.35%

Employees

Sector